Compare STRIDES PHARMA SCIENCE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs AUROBINDO PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE AUROBINDO PHARMA STRIDES PHARMA SCIENCE/
AUROBINDO PHARMA
 
P/E (TTM) x 42.7 19.7 217.4% View Chart
P/BV x 2.0 4.3 46.9% View Chart
Dividend Yield % 0.2 0.2 98.4%  

Financials

 STRIDES PHARMA SCIENCE   AUROBINDO PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147830 138.2%   
Low Rs642527 121.8%   
Sales per share (Unadj.) Rs317.2333.9 95.0%  
Earnings per share (Unadj.) Rs7.840.4 19.4%  
Cash flow per share (Unadj.) Rs25.151.8 48.4%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.20.4 60.7%  
Book value per share (Unadj.) Rs274.3237.1 115.7%  
Shares outstanding (eoy) m89.50585.91 15.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.82.0 138.7%   
Avg P/E ratio x114.016.8 678.2%  
P/CF ratio (eoy) x35.713.1 272.3%  
Price / Book Value ratio x3.32.9 114.0%  
Dividend payout %25.56.2 411.5%   
Avg Mkt Cap Rs m80,058397,569 20.1%   
No. of employees `0002.517.9 14.0%   
Total wages/salary Rs m4,34125,849 16.8%   
Avg. sales/employee Rs Th11,325.810,956.9 103.4%   
Avg. wages/employee Rs Th1,731.41,447.7 119.6%   
Avg. net profit/employee Rs Th280.11,324.3 21.1%   
INCOME DATA
Net Sales Rs m28,394195,636 14.5%  
Other income Rs m9411,553 60.6%   
Total revenues Rs m29,334197,189 14.9%   
Gross profit Rs m3,96539,519 10.0%  
Depreciation Rs m1,5406,680 23.1%   
Interest Rs m1,9622,626 74.7%   
Profit before tax Rs m1,40331,767 4.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-881 49.5%   
Tax Rs m977,269 1.3%   
Profit after tax Rs m70223,645 3.0%  
Gross profit margin %14.020.2 69.1%  
Effective tax rate %6.922.9 30.3%   
Net profit margin %2.512.1 20.5%  
BALANCE SHEET DATA
Current assets Rs m24,836153,645 16.2%   
Current liabilities Rs m18,993120,429 15.8%   
Net working cap to sales %20.617.0 121.2%  
Current ratio x1.31.3 102.5%  
Inventory Days Days71135 52.5%  
Debtors Days Days11364 178.1%  
Net fixed assets Rs m34,289103,909 33.0%   
Share capital Rs m895586 152.8%   
"Free" reserves Rs m23,651138,322 17.1%   
Net worth Rs m24,546138,908 17.7%   
Long term debt Rs m15,5131,800 862.1%   
Total assets Rs m65,437264,544 24.7%  
Interest coverage x1.713.1 13.1%   
Debt to equity ratio x0.60 4,878.7%  
Sales to assets ratio x0.40.7 58.7%   
Return on assets %4.19.9 41.0%  
Return on equity %2.917.0 16.8%  
Return on capital %6.923.8 28.9%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m15,69797,316 16.1%   
Fx outflow Rs m73540,589 1.8%   
Net fx Rs m14,96256,727 26.4%   
CASH FLOW
From Operations Rs m1,87116,220 11.5%  
From Investments Rs m5,826-28,768 -20.3%  
From Financial Activity Rs m-10,15719,191 -52.9%  
Net Cashflow Rs m-2,6156,656 -39.3%  

Share Holding

Indian Promoters % 27.7 54.1 51.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 8.0 475.5%  
FIIs % 8.6 27.7 31.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.2 253.9%  
Shareholders   56,241 69,601 80.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ELDER PHARMA  ALEMBIC  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Asian Paints Rallies 7% Post Q4 Results(09:30 am)

Asian stock markets climbed today after US benchmarks halted a three-day slide, with signs of a strengthening labor market outweighing investors' concerns about rising inflation.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 14, 2021 10:30 AM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS